MicuRx is a global biopharmaceutical company committed to discover, develop, and deliver innovative medicines that address unmet clinical needs. Founded in 2007, MicuRx’s headquarter is now located in Shanghai with branches in California, Hong Kong and Beijing. The companys management and technical teams have extensive industrial experience and exquisite professional skill in drug research and development, clinical research, regulatory affairs, manufacturing management and commercialization.
Location: United States
Employees: 51-200
Total raised: $112.8M
Founded date: 2007
Investors 1
| Date | Name | Website |
| - | CARB-X | carb-x.org |
Funding Rounds 5
| Date | Series | Amount | Investors |
| 19.08.2020 | - | $7.8M | - |
| 07.12.2017 | - | $15M | - |
| 26.09.2016 | Series C | $55M | - |
| 22.08.2013 | Series B | $25M | - |
| 26.06.2007 | - | $10M | - |
Mentions in press and media 20
| Date | Title | Description |
| 29.01.2026 | MicuRx Announces FDA Clearance of IND Application to Proceed to Phase 2a Trial of MRX-5 in Patients with Mycobacterium abscessus Pulmonary Disease | FOSTER CITY, Calif., Jan. 29, 2026 /PRNewswire/ -- MicuRx Pharmaceuticals, Inc. ("MicuRx"), a clinical-stage biopharmaceutical company focused on developing novel anti-infective therapies for drug-resistant bacterial infections, r... |
| 08.04.2025 | MicuRx: 15 Clinical and Preclinical Research Studies to be Presented at ESCMID Global 2025 | SHANGHAI, April 8, 2025 /PRNewswire/ -- The 2025 European Congress of Clinical Microbiology and Infectious Diseases (ESCMID Global 2025) will take place in Vienna from April 11 to 15, 2025. As one of the largest, most comprehensive, and inf... |
| 02.01.2025 | FDA Grants Orphan Drug Designation to MicuRx's MRX-5 for NTM Infections | SHANGHAI, Jan. 2, 2025 /PRNewswire/ -- Shanghai MicuRx Pharmaceutical Co., Ltd. ("MicuRx"，688373.SH) announced that MRX-5, its self-developed anti-infection drug, has been granted Orphan Drug Designation (ODD) by the U.S. Food and... |
| 29.11.2024 | MicuRx: Successfully Completes Phase III Clinical Trial of MRX-4 for Injection in China | SHANGHAI, Nov. 29, 2024 /PRNewswire/ -- Recently, Shanghai MicuRx Pharmaceutical Co., Ltd. ("MicuRx", 688373.SH) announced the successful completion of its Phase III clinical trial of MRX-4 for injection transitioning to oral Cont... |
| 25.10.2024 | MicuRx Announces the Successful Completion of Phase 1 Clinical Trial of MRX-5 in Australia | SHANGHAI, Oct. 25, 2024 /PRNewswire/ -- Recently, Shanghai MicuRx Pharmaceutical Co., Ltd. ("MicuRx", 688373.SH) announced the successful completion of Phase I clinical trial of MRX-5 in Australia, a self-developed oral antibacter... |
| 18.10.2024 | MicuRx Pharmaceuticals Showcases the Pipeline Status of MRX-5 and MRX-8 at BIO Investor Forum | SAN FRANCISCO, Oct. 18, 2024 /PRNewswire/ -- Dr. Regis Vilchez, Chief Medical Officer of MicuRx Pharmaceuticals, presented the latest advancements of company's development program, MRX-5 and MRX-8, at the BIO Investor Forum (BIF). These dev... |
| 08.10.2024 | MicuRx Pharmaceuticals Announces Promising Results from MRX-5 Study for Treating Mycobacterium abscessus Infections | FOSTER CITY, Calif., Oct. 8, 2024 /PRNewswire/ -- MicuRx Pharmaceuticals is excited to announce the publication of groundbreaking research on MRX-5, a novel oral oxaborole prodrug, demonstrating significant potential in the treatment of pul... |
| 18.07.2024 | MicuRx Presents Innovative Antibiotic Research Results at the 7th World Bronchiectasis Conference | MicuRx showcased the latest research progress on their pipeline products, MRX-5 and MRX-8, at the 7th World Bronchiectasis Conference Three significant study results further support the potential of MRX-5 and MRX-8 in treating Nontuberculou... |
| 18.07.2024 | MicuRx Presents Innovative Antibiotic Research Results at the 7th World Bronchiectasis Conference | MicuRx showcased the latest research progress on their pipeline products, MRX-5 and MRX-8, at the 7th World Bronchiectasis Conference Three significant study results further support the potential of MRX-5 and MRX-8 in treating Nontuberculou... |
| 06.06.2024 | MicuRx: Successful Completion of Phase I Clinical Trial for Self-Developed MRX-8 Antibacterial Drug in China | According to the World Health Organization (WHO), millions of patients face treatment difficulties or even life-threatening conditions due to resistant bacterial infections each year. MRX-8 not only shows excellent safety and tolerability b... |
Show more